MedTrace Logo

Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis

NCT04545788 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-09-16

No results posted yet for this study

Summary

This study is a randomized, controlled, multi-center clinical study. The main purpose of this study was to study the efficacy and safety data of total oral short-term therapy as an alternative to injection in the treatment of newly diagnosed RR-TB patients.

Conditions

Interventions

DRUG

Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.

AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.

Sponsors & Collaborators

  • Beijing Chest Hospital

    lead OTHER

Principal Investigators

  • NAIHUI CHU, Doctor · Beijing Chest Hospital affiliated to Capital Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04545788 on ClinicalTrials.gov